# US 8,278,089 B2 · Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,089 B2
- Document ID: US8278089B2
- Status: Granted
- Kind: B2
- Application number: 13/180,779
- Filed: 2011-07-12
- Published: 2011-11-03
- Granted: 2012-10-02
- Earliest claimed: 2006-08-22
- Inventors: Carl Miller
- Web page: https://patentgrep.com/patent/US8278089B2

## CPC

- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are quick dissolve tablets, each including Lactobacillus delbrueckii subsp bulgaricus (LBD) and N-acetyl-glucosamine (NAG), as well as excipients, for oral mucosal administration, for improving the quality of life of Hepatitis C patients. Any formulation suitable for oral mucosal administration can be employed for administering the active ingredients in a sufficient dosage for therapeutic effect, one such formulation being: 50 mg of Lactobacillus delbrueckii subsp bulgaricus lysate strain YB-I 10 mg of N-acetyl D-glucosamine. Excipients can include one or more of, maltodextrin; xanthan gum; acesulfam K; lemon powder and a flavoring, e.g., juice; Mannitol TL-32-04, Microcrystalline Cellulose and Carrageenan, Fructose, PVP-XL TL-11-04, Gellan Gum, Citrus TL 1-04, Orange TL 19-04, Sucrolose TL-13-04, and Mg ST TL-13-04.

## Claims

### Claim 1

A formulation to treat Hepatitis C infected patients, active ingredients of said formulation consisting essentially of: Lactobacillus delbrueckii subsp bulgaricus freeze dried lysate, and N-acetyl-glucosamine; and
said formulation dissolving on oral mucosa and releasing the active ingredients in less than about one minute following administration.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the Lactobacillus delbrueckii subsp bulgaricus lysate is strain YB-I.

### Claim 3 (depends on 2)

The formulation of claim 2, wherein the formulation has 50 mg of Lactobacillus delbrueckii subsp bulgaricus lysate strain YB-I and 10 mg of N-acetyl D-glucosamine.

### Claim 4 (depends on 3)

The formulation of claim 3, wherein the formulation further includes excipients.

### Claim 5 (depends on 4)

The formulation of claim 4, wherein the excipients are maltodextrin; xanthan gum; acesulfame K; lemon powder and a flavoring.

### Claim 6 (depends on 4)

The formulation of claim 4, wherein the excipients are Mannitol, Microcrystalline Cellulose and Carrageenan, Fructose, PVP, Gellan Gum, Citrus-flavor Sucralose, and Mg stearate.

### Claim 7 (depends on 1)

The formulation of claim 1, wherein treating patients results into an improvement in quality of life indicated by a two point or greater improvement in SF-36 scores.

### Claim 8 (depends on 1)

The formulation of claim 1, wherein the formulation is a tablet and dissolves within 30 to 45 seconds following administration.

### Claim 9

A fast dissolving tablet for treating Hepatitis C infected patients, said tablet consisting of active ingredients and excipients, said active ingredients being four parts of Lactobacillus delbrueckii subsp bulgaricus freeze dried lysate, and one part of N-acetyl-glucosamine.

### Claim 10 (depends on 9)

The tablet of claim 9, wherein the tablet consists of 9.1% of active ingredients, 52.8% of mannitol, 15.0% of microcrystalline cellulose and carrageenan, 12.5% of fructose, 5.0% of PVP, 0.5% of Gellan Gum, 3.0% of Citrus flavor, 1.0% Orange-flavor 0.5% Sucralose and 0.6% of Mg stearate.

### Claim 11

A formulation to improve quality of life of Hepatitis C patients by a two point or greater improvement in SF-36 scores, active ingredients of said formulation consisting essentially of:
Lactobacillus delbrueckii subsp bulgaricus freeze dried lysate, and N-acetyl-glucosamine; and
said formulation dissolving on oral mucosa and releasing the active ingredients in less than about one minute following administration.
